Literature DB >> 8627751

In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.

J A Mikovits1, P M Hoffman, A Rethwilm, F W Ruscetti.   

Abstract

The infectivity of human foamy virus (HFV) was examined in primary and cultured human leukocytes. Cell-free infectious viral stocks of HFV were prepared from the human kidney cell line 293 transfected with an infectious molecular clone of HFV. HFV productively infects a variety of human myeloid and lymphoid cell lines. In addition, primary cell cultures enriched for human CD4+, monocytes and brain-derived microglial cells, were readily infected by HFV. Interestingly, while infected primary CD4+ lymphocytes and microglial cells showed marked cytopathology characteristic of foamy virus, HFV-infected monocyte-derived macrophages failed to show any cytopathology. In addition, marked cytotoxicity due to HFV infection was seen in both human T-cell leukemia virus type 1- and human immunodeficiency virus type 1-infected T-cell lines and in human immunodeficiency virus type 1-infected monocytoid cell lines. Thus, HFV infection produces differential cytopathology in a wide host range of primary human leukocytes and hematopoietic cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627751      PMCID: PMC190134     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  Regulation of foamy virus gene expression.

Authors:  A Rethwilm
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

2.  Nuclear localization of foamy virus Gag precursor protein.

Authors:  A W Schliephake; A Rethwilm
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  Isolation of a new foamy retrovirus from orangutans.

Authors:  M O McClure; P D Bieniasz; T F Schulz; I L Chrystie; G Simpson; A Aguzzi; J G Hoad; A Cunningham; J Kirkwood; R A Weiss
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Human spumavirus replication in human cells.

Authors:  P C Loh; F M Matsuura
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

5.  Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells.

Authors:  D Derse; J Mikovits; M Polianova; B K Felber; F Ruscetti
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.

Authors:  S F Yu; M L Linial
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Absence of foamy virus DNA in Graves' disease.

Authors:  M Schweizer; R Turek; M Reinhardt; D Neumann-Haefelin
Journal:  AIDS Res Hum Retroviruses       Date:  1994-05       Impact factor: 2.205

8.  Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans.

Authors:  M Schweizer; R Turek; H Hahn; A Schliephake; K O Netzer; G Eder; M Reinhardt; A Rethwilm; D Neumann-Haefelin
Journal:  AIDS Res Hum Retroviruses       Date:  1995-01       Impact factor: 2.205

9.  Replicating foamy virus-based vectors directing high level expression of foreign genes.

Authors:  M Schmidt; A Rethwilm
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

Review 10.  Recent insights into the biology of the human foamy virus.

Authors:  A Saïb; J Périès; H de Thé
Journal:  Trends Microbiol       Date:  1995-05       Impact factor: 17.079

View more
  16 in total

1.  An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.

Authors:  P A Goepfert; K Shaw; G Wang; A Bansal; B H Edwards; M J Mulligan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Restriction of foamy viruses by APOBEC cytidine deaminases.

Authors:  Frédéric Delebecque; Rodolphe Suspène; Sara Calattini; Nicoletta Casartelli; Ali Saïb; Alain Froment; Simon Wain-Hobson; Antoine Gessain; Jean-Pierre Vartanian; Olivier Schwartz
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Packaging cell lines for simian foamy virus type 1 vectors.

Authors:  M Wu; A Mergia
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins.

Authors:  D Lindemann; M Bock; M Schweizer; A Rethwilm
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 5.  Historical perspective of foamy virus epidemiology and infection.

Authors:  C D Meiering; M L Linial
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Innate sensing of foamy viruses by human hematopoietic cells.

Authors:  Réjane Rua; Alice Lepelley; Antoine Gessain; Olivier Schwartz
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

7.  cis-Acting sequences required for simian foamy virus type 1 vectors.

Authors:  M Wu; S Chari; T Yanchis; A Mergia
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  In vivo cellular tropism of gorilla simian foamy virus in blood of infected humans.

Authors:  Rejane Rua; Edouard Betsem; Thomas Montange; Florence Buseyne; Antoine Gessain
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Cocirculation of Two env Molecular Variants, of Possible Recombinant Origin, in Gorilla and Chimpanzee Simian Foamy Virus Strains from Central Africa.

Authors:  Léa Richard; Réjane Rua; Edouard Betsem; Augustin Mouinga-Ondémé; Mirdad Kazanji; Eric Leroy; Richard Njouom; Florence Buseyne; Philippe V Afonso; Antoine Gessain
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

Review 10.  Non-simian foamy viruses: molecular virology, tropism and prevalence and zoonotic/interspecies transmission.

Authors:  Timo Kehl; Juan Tan; Magdalena Materniak
Journal:  Viruses       Date:  2013-09-13       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.